SCHEMBL5136850

SCHEMBL5136850

CCCCn1c(CN(Cc2ccccc2F)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
CYP2C19 P33261 2/20 0.36
ICMT O60725 1/20 0.35
CNR2 P34972 2/20 0.35
ADRB2 P07550 1/20 0.35
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
NR1H3 Q13133 1/20 0.34
C5AR1 P21730 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
CNR1 P21554 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
PDE4B Q07343 1/20 0.33
SLC2A1 P11166 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134519 0.94 TSHR (0.38) TSHRCYP2C19ICMTCNR2CYP1A2
SCHEMBL5134669 0.93 TSHR (0.37) TSHRCYP2C19ICMTCNR2NR1H3
SCHEMBL5138104 0.92 TSHR (0.36) TSHRCYP2C19ICMTCNR2C5AR1
SCHEMBL5072389 0.90 TSHR (0.41) TSHRCYP2C19CNR2CYP1A2CYP2D6
SCHEMBL5135274 0.90 TSHR (0.41) TSHRCYP2C19CNR2CYP1A2CYP2D6
SCHEMBL5137375 0.90 TSHR (0.36) TSHRCYP2C19ICMTCNR2CYP1A2
SCHEMBL5135027 0.90 TSHR (0.36) TSHRCYP2C19ICMTCNR2CYP1A2
SCHEMBL5136057 0.89 TSHR (0.37) TSHRCYP2C19ICMTCNR2NR1H3
SCHEMBL5136123 0.89 C5AR1 (0.38) TSHRCYP2C19ICMTCNR2C5AR1
SCHEMBL5136778 0.89 TSHR (0.39) TSHRCYP2C19CNR2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed